GlaxoSmithKline Rating Reiterated by JPMorgan Chase & Co. (GSK)
GlaxoSmithKline (LON:GSK)‘s stock had its “neutral” rating restated by JPMorgan Chase & Co. in a research note issued on Wednesday, American Banking & Market News reports. They currently have a GBX 1,900 ($29.71) target price on the stock. JPMorgan Chase & Co.’s price target points to a potential upside of 17.36% from the company’s current price.
A number of other firms have also recently commented on GSK. Analysts at Jefferies Group cut their price target on shares of GlaxoSmithKline (LON:GSK) from GBX 1,825 ($28.53) to GBX 1,800 ($28.14) in a research note to investors on Tuesday. They now have a “hold” rating on the stock. Separately, analysts at Bank of America Corp. reiterated a “buy” rating on shares of GlaxoSmithKline (LON:GSK) in a research note to investors on Tuesday. They now have a GBX 2,050 ($32.05) price target on the stock. Finally, analysts at Societe Generale reiterated a “buy” rating on shares of GlaxoSmithKline (LON:GSK) in a research note to investors on Monday. They now have a GBX 2,000 ($31.27) price target on the stock.
Five equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of GBX 1,644.93 ($25.72).
GlaxoSmithKline (LON:GSK) traded up 1.28% during mid-day trading on Wednesday, hitting GBX 1619.00. The stock had a trading volume of 11,157,370 shares. GlaxoSmithKline has a 52-week low of GBX 1194.5601 and a 52-week high of GBX 1816.00. The stock’s 50-day moving average is GBX 1669. and its 200-day moving average is GBX 1635.. The company’s market cap is £78.441 billion.
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.